Reuters logo
6 months ago
BRIEF-Trevena reports positive top-line results from two phase 3 pivotal efficacy studies of intravenous oliceridine
February 21, 2017 / 12:30 PM / 6 months ago

BRIEF-Trevena reports positive top-line results from two phase 3 pivotal efficacy studies of intravenous oliceridine

Feb 21 (Reuters) - Trevena Inc:

* Trevena announces positive top-line results from two phase 3 pivotal efficacy studies of intravenous oliceridine in moderate-to-severe acute pain

* Trevena inc says in both studies, oliceridine was generally safe and well-tolerated

* Trevena inc - program is on track for nda submission in 4q 2017

* Trevena inc says oliceridine program is on track for nda submission in 4q 2017

* Trevena -additional clinical, non-clinical, manufacturing activities remain on track to support nda submission in q4 of this year for oliceridine program Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below